Real-world Clinical Outcomes of the MITRIS RESILIA Mitral Valve
← catalyst calendarNCT05526560 · readout ≤ 530 d
Sponsored by Edwards Lifesciences (industry) · EW — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
504actual
Sites
34
Countries
Canada, Germany, United Kingdom +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-01-11 | actual | When the study began enrolling |
| Primary completion | Jan 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2035 | estimated | The whole study's end, after follow-up |
| First posted | 2022-09-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Mitral Stenosis
- Mitral Valve Insufficiency
Intervention
- Device: MITRIS RESILIA Mitral Valve, Model 11400M
Primary outcomes
what the primary-completion date above is the date OFFreedom from valve related death or valve related reintervention
measured 1 year
Hemodynamic performance as measured by peak and mean gradient by echocardiography
measured 1 year
Permalink · EW's whole pipeline · Catalyst calendar · Every registered study · What changed